Immunotherapies against HER2-Positive Breast Cancer
| Autor: | Macarena Roman Alonso, Joaquin Arribas, Santiago Duro Sánchez |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Duro-Sánchez S, Alonso MR] Preclinical & Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain. [Arribas J] Preclinical & Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain. Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: |
Cancer Research
Mama - Càncer - Prognosi neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES] Vaccines Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] CAR-Ts Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES] terapéutica::terapia biológica::inmunomodulación::inmunoterapia [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] Resistance Other subheadings::/therapy [Other subheadings] afecciones patológicas signos y síntomas::procesos patológicos::atributos de la enfermedad::progresión de la enfermedad [ENFERMEDADES] TCBs Oncology HER2 Mama - Càncer - Immunoteràpia Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression [DISEASES] Immunotherapy Otros calificadores::/terapia [Otros calificadores] |
| Zdroj: | Scientia |
| Popis: | A wide range of treatments are available for HER2-positive breast cancer, which have greatly improved the prognosis and quality of life of these patients. However, resistance to HER2-targeted or untargeted therapies is common in clinical practice and is associated with metastasis, recurrence, and cancer-related death. To address this clinical need, researchers are exploring immunotherapeutic approaches to completely eradicate tumor cells and prevent tumor relapse and progression. In this review, we focus on how these emerging strategies can overcome current resistance and improve the prognosis of patients who do not respond to standard therapies. Breast cancer is the leading cause of cancer-related deaths among women worldwide. HER2-positive breast cancer, which represents 15–20% of all cases, is characterized by the overexpression of the HER2 receptor. Despite the variety of treatments available for HER2-positive breast cancer, both targeted and untargeted, many patients do not respond to therapy and relapse and eventually metastasize, with a poor prognosis. Immunotherapeutic approaches aim to enhance the antitumor immune response to prevent tumor relapse and metastasis. Several immunotherapies have been approved for solid tumors, but their utility for HER2-positive breast cancer has yet to be confirmed. In this review, we examine the different immunotherapeutic strategies being tested in HER2-positive breast cancer, from long-studied cancer vaccines to immune checkpoint blockade, which targets immune checkpoints in both T cells and tumor cells, as well as the promising adoptive cell therapy in various forms. We discuss how some of these new approaches may contribute to the prevention of tumor progression and be used after standard-of-care therapies for resistant HER2-positive breast tumors, highlighting the benefits and drawbacks of each. We conclude that immunotherapy holds great promise for the treatment of HER2-positive tumors, with the potential to completely eradicate tumor cells and prevent the progression of the disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|